“The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its products. Cytomedix is also pursuing opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics, as well as actively seeking complementary products for the wound care market. The Company also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing, or sale".
Well‐rounded portfolio across multiple patent families Process, Formulation, and Method AutoloGel TM Treating Damaged Tissue Wounds, Bones, Other Tissue for Biomarkers for treatment efficacy Peptides with anti-inflammatory properties (CT-112) Peptides with angiogenic properties.
Cytomedix has awarded patent licenses to: – De Puy Spine, Inc., Division of J&J – Medtronic, Inc. – COBE Cardiovascular, Inc. – Biomet Biologics, Inc. – Smith and Nephew – Harvest Technologies, Inc. – Perfusion Partners and Associates, Inc. – SafeBlood Technologies, Inc. – CellMedix, Inc
Number of Patents United States International Granted 8 22 Pending 1 4